Breast, gastric and prostate cancer associated antigens and uses therefor

• US 7,166,573 B1
• Filed: 05/26/2000
• Issued: 01/23/2007
• Est. Priority Date: 05/28/1999
• Status: Expired due to Fees

• Current Assignee: Ludwig Institute for Cancer Research, Ltd.
• Original Assignee: Ludwig Institute for Cancer Research, Ltd.
• Inventors: Obata, Yuichi
• Primary Examiner(s): Siew; Jeffrey
• Assistant Examiner(s): FETTEROLF, BRANDON J
• Application Number:
  US09/979,932
• Time in Patent Office: 2,433 Days
• Field of Search: 435/7.1, 435/7.23, 435/7.92, 530/350, 530/387.1
• US Class Current: 435/7.1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: G01N 33/574 for cancer

Abstract

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast, gastric and prostate cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

Claims

1. A method of diagnosing prostate cancer comprising:

contacting a biological sample isolated from a subject with an antibody or antigen binding fragment thereof that specifically binds with an expression product of a nucleic acid molecule, which is (a) a nucleic acid molecule that encodes a polypeptide having at least 99% sequence identity to the amino acid sequence of SEQ ID NO;

1218, (b) a nucleic acid molecule that differs from SEQ ID NO;

504 in codon sequence due to degeneracy of the genetic code, or (c) a full length complement of (a) or (b), and

determining the interaction between the antibody or antigen binding fragment thereof and the expression product, wherein a determination that the antibody or antigen binding fragment thereof interacts with the expression product indicates that the expression product is present in the sample and that the patient has prostate cancer.

2. The method of claim 1, wherein the antibody is an antibody that binds to the expression product.

3. The method of claim 2, wherein the antibody is a polyclonal antisera or obtained from a polyclonal antisera.

4. The method of claim 2, wherein the antibody is a monoclonal antibody.

5. The method of claim 2, wherein the method is carried out as an ELISA assay.

6. The method of claim 2, wherein the method is carried out as a western blot.

7. The method of claim 2, wherein the method is carried out as an immunoprecipitation.

8. The method of claim 1, wherein the sample is a tissue sample.

9. The method of claim 8, wherein the tissue sample is a tissue biopsy.

10. The method of claim 1, wherein the sample is a cell sample.

11. The method of claim 10, wherein the cell sample is a cell scraping.

12. The method of claim 1, wherein the sample is blood or other bodily fluid.